Lipella Pharmaceuticals Inc (LIPO)

Apr 23, 2025, 8:30 AM EDT - 5 days ago

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Mar 7, 2025, 4:56 PM EST - 7 weeks ago

Spartan Capital Securities, LLC Announces Key February Transactions

HCTI

Mar 4, 2025, 1:18 PM EST - 7 weeks ago

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement

Feb 11, 2025, 10:52 AM EST - 2 months ago

Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes

Feb 6, 2025, 6:00 AM EST - 2 months ago

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Jan 10, 2025, 1:24 PM EST - 3 months ago

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement

Dec 31, 2024, 11:55 AM EST - 4 months ago

Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions

Dec 18, 2024, 2:28 PM EST - 4 months ago

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement

Nov 1, 2024, 4:30 PM EDT - 6 months ago

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Sep 25, 2024, 8:30 AM EDT - 7 months ago

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

Nov 10, 2023, 8:00 AM EST - 1 year ago

FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

Oct 25, 2023, 4:05 PM EDT - 1 year ago

Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 20, 2023, 10:47 AM EDT - 1 year ago

Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment

Oct 20, 2023, 8:00 AM EDT - 1 year ago

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus

Sep 21, 2023, 8:30 AM EDT - 1 year ago

Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology

May 15, 2023, 9:17 AM EDT - 2 years ago

Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

May 1, 2023, 8:30 AM EDT - 2 years ago

Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting

Apr 17, 2023, 8:30 AM EDT - 2 years ago

Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

Apr 5, 2023, 8:30 AM EDT - 2 years ago

Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent

Mar 31, 2023, 8:00 AM EDT - 2 years ago

Lipella Provides Business Update and Reports 2022 Financial Results

Mar 16, 2023, 8:30 AM EDT - 2 years ago

Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association

Mar 1, 2023, 8:00 AM EST - 2 years ago

Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board

Jan 11, 2023, 7:30 AM EST - 2 years ago

Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10

Jan 9, 2023, 8:00 AM EST - 2 years ago

Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco